Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Extensive Stage Small Cell Lung Cancer
Clinical trial register · United States · industry-sponsored

Extensive Stage Small Cell Lung Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9175 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 30 Oct 2026, 03:16 UTC
9175
Studies in scope
industry-sponsored, all four open statuses
4974
Recruiting now
open to new participants
2201
Lead sponsors
across recruiting studies
Top states
Florida 11 California 10 Illinois 9 Georgia 7 Arizona 5
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Extensive Stage Small Cell Lung Cancer trials in the USA

14 of 9175 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Jazz Pharmaceuticals
Phase 2
50
California, Florida, Georgia, Kentucky, South Carolina
2026-11-30
Recruiting
Amgen
Phase 1
380
Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Missouri, New York
2025-09-16
Active, closed
Amgen
Phase 3
350
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-08-18
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Recruiting
BioNTech SE
Phase 3
621
Arizona, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana
2025-02-03
Recruiting
Amgen
Phase 1
220
California, Illinois, Michigan, South Dakota, Texas, Washington
2024-10-07
Active, closed
BioNTech SE
Phase 2
110
Alaska, California, Florida, Illinois, Indiana, Kentucky, Minnesota, Missouri
2024-08-05
Recruiting
Daiichi Sankyo
Phase 1/2
123
Alabama, Arizona, California, Florida, Illinois, Michigan, Minnesota, New Hampshire
2024-07-22
Active, closed
Amgen
Phase 3
563
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2024-06-05
Active, closed
Shanghai Henlius Biotech
Phase 3
200
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2022-11-18
Active, closed
Amgen
Phase 1
184
California, Delaware, Michigan, New Jersey, New York, North Carolina, South Dakota, Washington
2022-08-24
Active, closed
Novartis Pharmaceuticals
Phase 1/2
55
Florida, Georgia, Kentucky, Missouri, New Jersey, Ohio, Pennsylvania
2022-07-13
Active, closed
Daiichi Sankyo
Phase 2
187
Arkansas, Florida, Illinois, Maryland, Massachusetts, Michigan, Missouri, New Jersey
2022-03-09
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/extensive-stage-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,175 studies in total at the last sync on 30 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies listing the condition Extensive Stage Small Cell Lung Cancer.

How many Extensive Stage Small Cell Lung Cancer trials are recruiting in the US?

7 of the 14 studies on this page are recruiting new participants as of the 30 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Extensive Stage Small Cell Lung Cancer), 14 studies
PhaseStudiesRecruitingShare
Phase 35235.7%
Phase 13221.4%
Phase 1/23221.4%
Phase 23121.4%

Most active sponsors

Lead sponsors with the most studies (Extensive Stage Small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
Amgen52
BioNTech SE21
Daiichi Sankyo21
Novartis Pharmaceuticals21
Bristol-Myers Squibb11
Jazz Pharmaceuticals11
Shanghai Henlius Biotech10

Top states

Top states (Extensive Stage Small Cell Lung Cancer), by number of studies with a site there
StateStudies
Florida11
California10
Illinois9
Georgia7
Arizona5
Kentucky5
Missouri5
Alabama4
Arkansas4
Indiana4
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.